Oral Morphine Conversion from Intravenous Therapy: Clinical Implications and Personalized Dosing Strategies

Abstract

Morphine remains the cornerstone opioid medication used to treat patients who experience moderate to severe pain during their acute medical treatment, their cancer treatments, and their palliative care. Medical professionals use Intravenous (IV) administration to deliver immediate pain relief, but they must switch patients to oral medication for their ongoing treatment because it helps patients move better, decreases healthcare expenses, and enhances their overall well-being. The review assesses how pharmacokinetic principles, dose equivalence methods, and safety factors affect the process of converting morphine from intravenous to oral use. The researchers performed a structured literature review, which accessed three databases: PubMed, Scopus, and Web of Science, to gather information from 2010 to 2025. The researchers selected studies that included clinical trials and observational studies and international guidelines that examined how adults convert from IV-to-oral morphine. Evidence supports a standard IV-to-oral conversion ratio of 1:3, which shows that patients absorb 30 to 40 percent of the drug through oral administration. The conversion process needs calculation of the complete 24-hour intravenous dosage, which gets multiplied by three before being divided into the scheduled oral dosages, together with the additional breakthrough dosages, which make up 10 to 15 percent of the overall daily amount. The need for dose adjustments arises from factors that include a person's age, together with their kidney and liver health, their history of opioid use, and their existing medical conditions. The system requires safety monitoring to protect against respiratory depression and sedation, nausea, and constipation. The use of standardized conversion protocols, which enable personalized patient treatment, results in better pain management, greater patient adherence, and improved care for patients who leave the hospital. The upcoming methods for developing personalized opioid treatment will benefit from the combination of pharmacogenomics and digital predictive models.